Brief: Little Green Pharma Says Received Ethics Approval For Cbd Phase Iii Clinical Trial
30/11/2022 01:36
Nov 30 (Reuters) - Little Green Pharma Ltd LGP.AX :
* RECEIVED ETHICS APPROVAL FOR CBD PHASE III CLINICAL TRIAL
Source text for Eikon: ID:nASX1r9wwT
Further company coverage: LGP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Little Green Pharma
See all newsBrief: Little Green Pharma Appoints Jennifer Pilcher As CFO
Brief: Little Green Pharma Announces Resignation Of CFO
Brief: Little Green Pharma Says Cannatrek In Further Discussions With TGA In Relation To Investigation
Brief: Little Green Pharma Reports Qtrly Revenue Of A$12.5 Million
Brief: Little Green Pharma Announces Updated Second Court Date